AXGN
What one share of Axogen holds
Electromedical and Electrotherapeutic Apparatus
We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries.
Axogen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.07 |
|---|---|
| Profit | −$0.68 |
| Capex (buildings and equipment) | $0.13 |
| Free cash flow | $0.17 |
| Cash and investments | $1.76 |
| Debt | $0.00 |
| Book value | $4.78 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.34 | −$0.47 | $0.03 | −$0.40 | — | $0.45 |
| 2017 | $1.81 | −$0.31 | $0.03 | −$0.31 | — | $0.73 |
| 2018 | $2.26 | −$0.60 | $0.17 | −$0.65 | — | $3.78 |
| 2019 | $2.72 | −$0.74 | $0.12 | −$0.63 | — | $3.34 |
| 2020 | $2.81 | −$0.60 | $0.55 | −$0.79 | — | $3.03 |
| 2021 | $3.09 | −$0.65 | $0.67 | −$1.00 | — | $2.70 |
| 2022 | $3.29 | −$0.69 | $0.48 | −$0.86 | — | $2.38 |
| 2023 | $3.71 | −$0.51 | $0.32 | −$0.46 | — | $2.22 |
| 2024 | $4.23 | −$0.23 | $0.07 | $0.03 | — | $2.35 |
| 2025 | $4.89 | −$0.34 | $0.08 | −$0.06 | — | $2.73 |